Arch Venture Partners X, Llc - Net Worth and Insider Trading
Arch Venture Partners X, Llc Net Worth
The estimated net worth of Arch Venture Partners X, Llc is at least $407 Million dollars as of 2024-11-05. Arch Venture Partners X, Llc is the 10% Owner of Neumora Therapeutics Inc and owns about 29,545,420 shares of Neumora Therapeutics Inc (NMRA) stock worth over $346 Million. Arch Venture Partners X, Llc is also the 10% Owner of Prime Medicine Inc and owns about 15,456,594 shares of Prime Medicine Inc (PRME) stock worth over $61 Million. Details can be seen in Arch Venture Partners X, Llc's Latest Holdings Summary section.
Disclaimer: The insider information is derived from SEC filings. The estimated net worth is based on the final shares held after open market or private purchases and sales of common stock with a transaction code of "P" or "S" on Form 4, assuming that Arch Venture Partners X, Llc has not made any transactions after 2024-02-15 and currently still holds the listed stock(s). Please note that this estimate may not reflect the actual net worth.
Transaction Summary of Arch Venture Partners X, Llc
Arch Venture Partners X, Llc Insider Ownership Reports
Based on ownership reports from SEC filings, as the reporting owner, Arch Venture Partners X, Llc owns 6 companies in total, including Sienna Biopharmaceuticals Inc (SNNAQ) , Erasca Inc (ERAS) , and Sana Biotechnology Inc (SANA) among others .
Click here to see the complete history of Arch Venture Partners X, Llc’s form 4 insider trades.
Insider Ownership Summary of Arch Venture Partners X, Llc
Ticker | Comapny | Transaction Date | Type of Owner |
---|---|---|---|
SNNAQ | Sienna Biopharmaceuticals Inc | 2019-02-22 | 10 percent owner |
ERAS | Erasca Inc | 2021-07-15 | 10 percent owner |
SANA | Sana Biotechnology Inc | 2021-02-03 | 10 percent owner |
2021-06-16 | 10 percent owner | ||
2024-02-15 | 10 percent owner | ||
2023-09-19 | 10 percent owner |
Arch Venture Partners X, Llc Latest Holdings Summary
Arch Venture Partners X, Llc currently owns a total of 2 stocks. Among these stocks, Arch Venture Partners X, Llc owns 29,545,420 shares of Neumora Therapeutics Inc (NMRA) as of September 19, 2023, with a value of $346 Million and a weighting of 84.98%. Arch Venture Partners X, Llc also owns 15,456,594 shares of Prime Medicine Inc (PRME) as of February 15, 2024, with a value of $61 Million and a weighting of 15.02%.
Latest Holdings of Arch Venture Partners X, Llc
Ticker | Comapny | Latest Transaction Date | Shares Owned | Current Price ($) | Current Value ($) |
---|---|---|---|---|---|
NMRA | Neumora Therapeutics Inc | 2023-09-19 | 29,545,420 | 11.72 | 346,272,322 |
PRME | Prime Medicine Inc | 2024-02-15 | 15,456,594 | 3.96 | 61,208,112 |
Holding Weightings of Arch Venture Partners X, Llc
Arch Venture Partners X, Llc Form 4 Trading Tracker
According to the SEC Form 4 filings, Arch Venture Partners X, Llc has made a total of 1 transactions in Neumora Therapeutics Inc (NMRA) over the past 5 years, including 1 buys and 0 sells. The most-recent trade in Neumora Therapeutics Inc is the acquisition of 1,500,000 shares on September 19, 2023, which cost Arch Venture Partners X, Llc around $26 Million.
According to the SEC Form 4 filings, Arch Venture Partners X, Llc has made a total of 2 transactions in Prime Medicine Inc (PRME) over the past 5 years, including 2 buys and 0 sells. The most-recent trade in Prime Medicine Inc is the acquisition of 3,200,000 shares on February 15, 2024, which cost Arch Venture Partners X, Llc around $20 Million.
Insider Trading History of Arch Venture Partners X, Llc
- 1
Arch Venture Partners X, Llc Trading Performance
GuruFocus tracks the stock performance after each of Arch Venture Partners X, Llc's buying transactions within different timeframes. To be detailed, the average return of stocks after 3 months bought by Arch Venture Partners X, Llc is 6.35%. GuruFocus also compares Arch Venture Partners X, Llc's trading performance to market benchmark return within the same time period. The performance of stocks bought by Arch Venture Partners X, Llc within 3 months outperforms 2 times out of 3 transactions in total compared to the return of S&P 500 within the same period.
You can select different timeframes to see how Arch Venture Partners X, Llc's insider trading performs compared to the benchmark.
Performance of Arch Venture Partners X, Llc
Arch Venture Partners X, Llc Ownership Network
Ownership Network List of Arch Venture Partners X, Llc
Ownership Network Relation of Arch Venture Partners X, Llc
Arch Venture Partners X, Llc Owned Company Details
What does Sienna Biopharmaceuticals Inc do?
Who are the key executives at Sienna Biopharmaceuticals Inc?
Arch Venture Partners X, Llc is the 10 percent owner of Sienna Biopharmaceuticals Inc. Other key executives at Sienna Biopharmaceuticals Inc include Chief Financial Officer Alexander Azoy , Chief Medical Officer Paul F. Lizzul , and director & President & CEO Iii Frederick Beddingfield .
Sienna Biopharmaceuticals Inc (SNNAQ) Insider Trades Summary
In summary, during the past 3 months, insiders sold 0 shares of Sienna Biopharmaceuticals Inc (SNNAQ) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of Sienna Biopharmaceuticals Inc (SNNAQ) were sold and 0 shares were bought by its insiders, resulting in a net sale of 0 shares.
Sienna Biopharmaceuticals Inc (SNNAQ)'s detailed insider trading history can be found in Insider Trading Tracker table.
Sienna Biopharmaceuticals Inc Insider Transactions
Arch Venture Partners X, Llc Mailing Address
Above is the net worth, insider trading, and ownership report for Arch Venture Partners X, Llc. You might contact Arch Venture Partners X, Llc via mailing address: 8755 W. Higgins Road, Suite 1025, Chicago Il 60631.